AMAL Therapeutics and Natera to Partner on Clinical Trial Using Signatera MRD Test to Assess Treatment Response to Colorectal Cancer Vaccine
Natera, Inc., a global leader in cell-free DNA testing, will partner with AMAL Therapeutics on a clinical trial focused on stage IV colorectal cancer. This study adds to the growing number of pharmaceutical trials using Natera’s SignateraTM molecular residual disease (MRD) assay as a biomarker to assess treatment response. View PDF
